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Jeffrey Roix and Saurabh Saha*Abstract
Background: Given the large medical burden of polycystic kidney disease (PKD) and recent clinical trial failures,
there is a need for novel, safe and effective treatments for the disorder.
Methods: In PCK rat and PKD2(ws25/w183) mouse models, entanercept was administered once every three days at 5
or 10 mg/kg, once daily. Mozavaptan was administered as a pilot control, provided continuously via milled chow at
0.1%. Animals were assessed for measures of pharmacodynamic response, and improvements in measures of
polycystic kidney disease.
Results: Entanercept treatment modulated inflammatory markers, but provided limited therapeutic benefit in
multiple animal models of established polycystic kidney disease. Kidney weight, cyst burden and renal function
markers remained unchanged following administration of etanercept at various dose levels and multiple treatment
durations.
Conclusions: While it remains possible that TNF-α inhibition may be effective in truly preventative settings, our
observations suggest this pathway is less likely to exhibit therapeutic or disease-modifying efficacy following the
standard clinical diagnosis of disease.
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As many as 1 in 20 patients on dialysis suffer from poly-
cystic kidney disease: this chronic, progressive disorder
emerges over years in patients who carry a spectrum of
well-characterized genetic alterations [1]. Autosomal dom-
inant and recessive mutations in the polycystin gene fam-
ily (PKHD1, PKD2) are thought to cause an array of
defects in basic renal epithelial cell function, which in turn
culminate in the hallmark cysts and kidney dysfunctions
characteristic of the disease [2,3].
Despite an understanding of both pathophysiologic and
correlative molecular genetic processes, effective and safe
treatments for PKD are not currently available, and recent
interventional trials for the disease have been disappoint-
ing. Preclinical studies highlighted the possible value of
targeting the vasopressin and mTOR/AKT pathways [4-6].
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reproduction in any medium, provided the orpathways, however, have suggested only marginal efficacy,
in the face of appreciable side effects [7-9].
In this setting, it is promising that studies of basic
biological processes associated with PKD pathophysi-
ology have yielded new therapeutic targets. TNF-α is a
canonical immune cytokine that activates inflammatory
signaling in disorders ranging from arthritis to bowel
disease [10,11]. Recently, this pathway was implicated in
fundamental cellular processes of PKD: active TNF-α
interferes with processing and membrane presentation
of PKD2, effectively phenocopying genetic ablation of
the disease locus. TNF-α was shown to be a both neces-
sary and sufficient modifier of polycystic kidney disease.
Intriguingly, TNF-α inhibition, using the approved bio-
logic drug etanercept, could prevent kidney cyst forma-
tion in animals heterozygous for PKD2 deficiency that
are normally predisposed to the disease [12].
While the genetic basis of PKD is understood, definitive
clinical diagnosis occurs only after the evolution of estab-
lished disease, when ultrasound is used to confirm the
presence of renal cysts [13]. Therefore, we sought toal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A rat colony homozygous for mutation at the Pkhd1 locus
(allele: PcK/Crljcrl-Pkhd1pck) was obtained from Charles
River (Wilmington, MA). Male rats were employed in
drug studies. Identification and characterization of this
spontaneous mutant colony has been described [14]. A
colony of PKD2 ws25/w183 compound heterozygous mice
(referred to herein as ws25/-) kindly provided by Albert
Einstein College of Medicine, and re-derived and main-
tained. Mice were genotyped by southern blots, and gener-
ally an equal number of male and female animals were
apportioned to each study group. The Taconic Animal
Care and Use Committee approved all study protocols.
Animals had free access to water and standard diets.
Experimental protocols
A summary of treatment and study design is included in
Table 1. Rats were obtained at three weeks of age, and accli-
mated for one week preceding treatment. Etanercept
(Enbrel, Amgen) was reconstituted regularly (vehicle 0.9%
benzyl alcohol in sterile water) and single aliquots were
used for a maximum of 4 days; dosing route was intraperi-
toneal (i.p.). Vehicle treatments were designed to match the
excipient composition: 200 mM mannitol, 30 mM sucrose,
1 mM tromethamine in sterile water, pH7.4. Mozavap-
tan was synthesized (Focus Synthesis, San Diego, CA)
and administered on a continuous basis via standard
diet milled at the indicated concentrations on a per-
weight basis. At the end of treatment, animals were
anesthetized by carbon dioxide inhalation. Kidneys were
removed and weighed; blood and serum was obtained
by cardiac puncture method. The left kidneys were
weighed and then fixed in 10% neutral-buffered forma-
lin for 48Hrs, processing for histologic examinations;
right kidneys were weighed and snap-frozen in dry ice
for biomarker protein assay work.
Kidneys were embedded, sectioned and stained with
hematoxylin and eosin (H&E) for histopathological evalu-
ation of the degrees and severity of cyst formation. Tissues
were sectioned longitudinally through the center keep the
location of assessments constant. Cyst number was assessed
by gross inspection and count from 3 random fields (×40
magnification) per animal, and averaged across cohorts.
Mice were weaned and allowed to acclimate to either
4 or 13 weeks of age before treatment began. Drug treat-
ments and subsequent tissue, blood and any biomarker
analyses were performed as described above.
In rats, water intake was assessed by periodically weigh-
ing cage bottles, and urine output was measured followingforced manual voiding. In mice, urine production was
assessed using metabolic cage monitoring; recording ses-
sions were acquired in two separate morning and evening
sessions, for two hours each. Mouse water consumption
was monitored through periodic cage bottle weighing.
Kinase signaling analysis
Kinase signaling was assessed on homogenized kidney
lysates using a multiplex, bead-based suspension protein
array service (AssayGate Inc, Ijamsville, MD).
Serum chemistry
Serum urea nitrogen levels and creatinine were measured
using a Beckman autoanalyzer and standard colorimetric
assessments (Beckman Instruments, Fullerton, CA).
Statistical analyses
Multiple group comparisons were performed using a
one-way ANOVA with post-test according to Dunnet.
P < 0.05 was considered statistically significant. Values
are expressed as means ± SEM.
Results and discussion
Initially, we studied the pck rat disease model, which har-
bors homozygous null mutations in the orthologous
PKHD1 susceptibility locus: this model of autosomal re-
cessive PKD (ARPKD) was previously used to study the
potential therapeutic effects of vasopressin and mTOR/
AKT pathway inhibitors [4,15]. We first established an op-
timal dosing protocol for etanercept, as the drug could
display unexpected pharmacokinetic and pharmacody-
namic effects in certain rodent models. These pilot studies
showed that, in kidneys analyzed following 4 weeks of
treatment, as little as 0.5 mg/kg etanercept dosed every
three days was sufficient to markedly reduce both NF-kB
(p65-S536) and p38 stress kinase pathway signaling, which
are established mechanistic biomarkers of TNF-a signaling
[16] (Figure 1A).
Having proven that etanercept could reduce relevant
inflammatory signaling in the kidneys of pck rats, we
next studied whether the drug could improve estab-
lished markers of renal function and PKD pathology. In
4-week old animals treated for one month, gross kidney
weights, as well as average cyst number quantified after
histological examination, were unchanged by etanercept
doses as high as 10 mg/kg (Figure 1B). Similarly, the
renal function markers blood urea nitrogen (BUN) and
creatinine remained unchanged following treatment
(Figure 1B). Other investigators have noted that rodent
models of PKD are sensitive to the timing and duration
of treatment [6]. Therefore, we tested prolonged etaner-
cept dosing at 5 mg/kg every 3 days for 8 weeks; in this
background, we additionally tested continuous adminis-
tration of the vasopressin antagonist mozavaptan at
Table 1 Treatment and methods summary for animal studies
Study Genotype Age at treatment Animals per arm Treatments Administration route Dose Schedule Treatment duration
ARPKD rat, short-term
therapeutic intervention
PcK/Crljcrl-Pkhd1pck 4 weeks 10 Vehicle NA NA NA 4 weeks
PcK/Crljcrl-Pkhd1pck 4 weeks 10 Mozavaptan i.p. 0.5, 5, 10 mg/kg Once, every third day 4 weeks
ARPKD rat, Long-term
therapeutic intervention
PcK/Crljcrl-Pkhd1pck 4 weeks 10 Vehicle NA NA NA 8 weeks
PcK/Crljcrl-Pkhd1pck 4 weeks 10 Mozavaptan Milled chow 0.10% ad libitum 8 weeks
PcK/Crljcrl-Pkhd1pck 4 weeks 10 Etanercept i.p. 5 mg/kg Once, every third day 8 weeks
ADPKD (PDK2 ws25/-) mouse,
therapeutic intervention
PKD2 ws25/- 12 weeks 14 Vehicle NA NA NA 8 weeks
PKD2 ws25/- 12 weeks 11 Mozavaptan Milled chow 0.10% ad libitum 8 weeks
PKD2 ws25/- 12 weeks 15 Etanercept i.p. 5 mg/kg Once, every third day 8 weeks
ADPKD (PDK2 ws25/-) mouse,
prophylactic intervention
PKD2 ws25/- 4 weeks 15 Vehicle NA NA NA 8 weeks
PKD2 ws25/- 4 weeks 15 Mozavaptan Milled chow 0.05% ad libitum 8 weeks























































































































Figure 1 Short-term (4 weeks) entanercept pharmacodynamics and efficacy in pck rats. (A) Stress kinase phosphorylation from kidney
tissue lysates (N = 4) is significantly reduced following 4 weeks dosing with etanercept at various levels. (B) Kidney weight, cyst number, serum
urea nitrogen and creatinine are unchanged following etanercept treatment for 4 weeks (N = 10).
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tan induced aquaretic effects, which confirmed that our
studies could properly recapitulate known pharmacologic
effects of this drug class. Still, in the more chronic treat-
ment setting, neither etanercept nor mozavaptan proved
efficacious against multiple therapeutic markers of PKD.
Surprisingly, both gross kidney weight and cyst number
were moderately increased in both drug treatment arms
(Table 2). While BUN was largely unchanged following
treatment, animals treated with either etanercept or moza-
vaptan had blood creatinine levels greater than untreatedanimals (Table 2). Given the previously observed effects of
vasopressin antagonists in preserving kidney volume and
reducing cysts [4,6], though, we conclude etanercept is
largely ineffective in this model of ARPKD.
Still, it remained possible etanercept could be effective
in models of autosomal dominant PKD (ADPKD). Here,
we studied mice hemizygous for the PKD2 ws25 allele;
this latent disease model rapidly develops cysts in a sto-
chastic fashion, following somatic recombination and
loss-of-heterozygosity [17]. We first tested etanercept in
13 week-old PKD2 ws25/- animals, which have previously





BUN (mg/dL) CREA (mg/dL) Water consumptiond
(mL/rat/day0029)
Vehicle 1.05 ± 0.023 9.2 ± 0.71 14.9 ± 0.51 0.63 ± 0.05 42.96 ± 1.96
Mozavaptan (0.1%) 1.12 ± 0.04 12.1 ± 1.4 16.2 ± 0.39 0.71 ± 0.03b 63.88 ± 0.56c
Etanercept (5 mg/kg) 1.16 ± 0.036 12 ± 1.3 16.4 ± 0.4 0.71 ± 0.06b 38.95 ± 1.40
aData shown are group average ± SEM, N=10.
bComparison between vehicle and treatment group(s), p < 0.05.
cComparison between vehicle and treatment group(s), p < 0.001.
dWater consumption measured over final week of treatment.
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tic kidney disease. Following dosing for 8 weeks, 5 mg/kg
etanercept did not improve kidney weight, cyst number,
or BUN. As in pck rats, we also administered 0.1% moza-
vaptan continuously via diet; perhaps surprisingly, this
treatment also proved ineffective across the multiple pa-
rameters investigated (Table 3).
Finally, we studied etanercept initiated at the earliest
time point achievable in in-vivo settings. Starting at 4
weeks of age, we administered either 5 or 10 mg/kg eta-
nercept to PDK2 ws25/- mice once every three days for
two months. As in pck rats, etanercept proved ineffect-
ive in treating various aspects of PKD: kidney weight,
and cyst number were not reduced following treatment,
and BUN also remained unchanged (Table 3). In total,
we conclude that, in settings that would reveal either
therapeutic or disease-modifying activities, etanercept is
largely ineffective at treating the key pathologic and
physiologic dysfunctions of PKD.
Conclusions
Considering our data in the context of prior mechanistic
and clinical studies, we suggest several key conclusions.
First, and most importantly, etanercept, and likely TNF-α
blockade in general, appears to be a relatively poor candi-
date therapeutic approach for study in future clinical trials.
Clinical trials of vasopressin and mTOR antagonists have
shown marginal efficacy and important side effects, des-







Vehicle 13 weeks 14 1.85 ± 0.17 6.7 ±
Mozavaptan (0.1%) 13 weeks 11 1.74 ± 0.11 6.9 ±
Etanercept (5 mg/kg) 13 weeks 15 1.75 ± 0.09 6.5 ±
Vehicle 4 weeks 15 1.96 ± 0.15 7.0 ±
Mozavaptan (0.05%) 4 weeks 15 1.78 ± 0.07 7.7 ±
Etanercept (10 mg/kg) 4 weeks 15 1.84 ± 0.2 5.5 ±
Etanercept (5 mg/kg) 4 weeks 15 1.77 ± 0.17 6.2 ±
aData shown are group average ± SEM.
bUrine production over 4 hours monitoring in metabolic cage; separate measure of
cComparison between vehicle and treatment group, p<0.05.our investigated parameters, in rodent models closely re-
lated those employed here. Our studies were powered to
discern therapeutic effects similar in magnitude as those
drugs currently in clinical testing. Therefore, TNF-α
blockade seems less attractive compared to other candi-
date therapeutic mechanisms both currently and prospect-
ively being assessed for clinical translation.
Second, our study underscores how fundamental mo-
lecular and cellular events observed in preclinical research
can be difficult to translate into treatments for disease
biology as it presents during common clinical practice.
Current clinical criteria dictate that, even in the presence
of strongly predictive genetic risk, formal diagnosis of
ADPKD requires the observation of cysts via ultrasound
exam [13]. By contrast, Li et al. showed that, in young
mice heterozygous for PKD2 loss, cyst formation could be
prevented by prophylactic etanercept [12]. While promis-
ing, the analogous application of this observation into
clinical practice would imply life-long dosing and conse-
quent immunosuppression, initiated in very young pa-
tients with a confirmed genetic background of PKD.
Preventative therapy along these lines would likely be diffi-
cult to test in clinical trials, and could also prove challen-
ging in everyday clinical practice.
Lastly, our data suggest additional, relevant hypotheses
concerning disease pathology and treatment in PKD. Pa-
tients presenting with PKD are likely phenotypically null
for essential polycystin gene function(s)–single PKHD1 or









0.7 20.6 ± 1.2 0.99 ± 0.20 4.0 ± 0.04
1.1 23.6 ± 2.0 4.93 ± 1.64c 11.1 ± 0.35c
0.8 20.1 ± 1.5 NA 4.0 ± 0.06
0.7 24.8 ± 2.7 NA 6.1 ± 0.18
0.8 26.1 ± 2.1 NA 9.6 ± 0.35c
0.6 21.9 ± 1.6 NA 5.9 ± 0.16
0.7 23.2 ± 2.0 NA 5.8 ± 0.18
daily water consumption, by bottle weighing.
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TNF-α blockade could rescue residual PKD2 activity, our
work suggests that later pathophysiological events in PKD
are largely TNF-α independent. Also, as TNF-α has been
long appreciated as a key, nodal point of inflammatory sig-
naling, it seems possible that other anti-inflammatory ap-
proaches may also prove ineffective in PKD—specifically,
approaches that simply decrease NF-kB or p38 stress kin-
ase signaling (as in our studies) may not sufficiently mod-
ify the underlying pathophysiology of PKD.
In summary, our studies have explored the possible
therapeutic benefit of TNF-α blockade in rodent models of
PKD previously used to nominate agents for interventional
clinical trials. We suggest our data de-prioritize this puta-
tive disease mechanism for future clinical testing in settings
of established disease. It remains possible, however, that al-
ternate anti-inflammatory approaches could be safe and ef-
fective treatments for PKD, and that chronic TNF-α
inhibition could prevent the emergence of PKD in patients
who are genetically “at-risk”, but harbor occult disease.
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